https://orcid.org/0000-0001-6916-2946
References
- Abusnina A, Lugnier C. 2017. Therapeutic potentials of natural compounds acting on cyclic nucleotide phosphodiesterase families. Cell Signal. 39:55–65.
- Ashtekar SS, Bhatia NM, Bhatia MS. 2018. Exploration of leads from natural domain targeting her2 in breast cancer: an in-silico approach. Int J Pept Res Ther. [accessed 2019 Jan 14]. https://doi.org/10.1007/s10989-018-9712-y.
- Berrougui H, Martin-Cordero C, Khalil A, Hmamouchi M, Ettaib A, Marhuenda E, Herrera MD. 2006. Vasorelaxant effects of harmine and harmaline extracted from Peganum harmala L. seed’s in isolated rat aorta. Pharmacol Res. 54(2):150–157.
- Chen J, Liu JH, Wang T, Xiao H, Yin C. 2010. Effects of tetrandrine on cAMP and cGMP levels in rabbit corpus cavernosum in vitro. Nat Prod Res. 24(12):1095–1103.
- Gonçalves RL, Lugnier C, Keravis T, Lopes MJ, Fantini FA, Schmitt M, Cortes SF, Lemos VS. 2009. The flavonoid dioclein is a selective inhibitor of cyclic nucleotide phosphodiesterase type 1 (PDE1) and a cGMP-dependent protein kinase (PKG) vasorelaxant in human vascular tissue. Eur J Pharmacol. 620(1-3):78–83.
- Hsu HT, Wang WH, Han CY, Chen CN, Chen CM, Ko WC. 2013. Inhibitory effects of hesperetin derivatives on guinea pig phosphodiesterases and their ratios between high- and low-affinity rolipram binding. J Pharm Sci. 102(7):2120–2127.
- Konstantinos G, Petros P. 2009. Phosphodiesterase-5 inhibitors: future perspectives. Curr Pharm Des. 15(30):3540–3551.
- Mohamad Rosdi MN, Mohd Arif S, Abu Bakar MH, Razali SA, Mohamed Zulkifli R, Ya'akob H. 2018. Molecular docking studies of bioactive compounds from Annona muricata Linn as potential inhibitors for Bcl-2, Bcl-w and Mcl-1 antiapoptotic proteins. Apoptosis. 23(1):27–40.
- Schellack N, Agoro A. 2014. A review of phosphodiesterase type 5 inhibitors. S Afr Fam Pract. 56(2):96–101.
- Shang N-N, Shao Y-X, Cai Y-H, Guan M, Huang M, Cui W, He L, Yu Y-J, Huang L, Li Z, et al. 2014. Discovery of 3-(4-hydroxybenzyl)-1-(thiophen-2-yl)chromeno[2,3-c]pyrrol-9(2H)-one as a phosphodiesterase-5 inhibitor and its complex crystal structure. Biochem Pharmacol. 89(1):86–98.
- Stirban A, Tamler R, Veresiu IA. 2011. Effects of PDE5 inhibitors on endothelial function and cardiovascular autonomic nerve function in men. J Mens Health. 8(2):109–118.
- Tollefson MB, Acker BA, Jacobsen EJ, Hughes RO, Walker JK, Fox DNA, Palmer MJ, Freeman SK, Yu Y, Bond BR. 2010. 1-(2-Ethoxyethyl)-1H-pyrazolo[4,3-d]pyrimidines as potent phosphodiesterase 5 (PDE5) inhibitors. Bioorg Med Chem Lett. 20(10):3120–3124.
- World Health Organization (WHO). 2017. World health statistics 2017: monitoring health for the SDGs, sustainable development goals. Geneva: World Health Organization.
- Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, Bohm M, Sybrecht GW. 2001. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 104(11):1218–1222.
- Yu SM, Cheng ZJ, Kuo SC. 1995. Endothelium-dependent relaxation of rat aorta by butein, a novel cyclic AMP-specific phosphodiesterase inhibitor. Eur J Pharmacol. 280(1):69–77.